Berufserfahrung

• Patentanwaltskandidatin, V.O. (2019-heute)
• 2014-2018 PhD Universität Utrecht

Ausbildung

• PhD Infection and Immunity, Universität Utrecht (2019)
• MSc Infection and Immunity, Universität Utrecht (2014)
• BSc Biomedizinische Wissenschaften, Universität Utrecht (2012)

Publikationen

• M. Mues, L. Karra, D. Romero-Moya, A. Wandler, M. J. Hangauer, O. Ksionda, Y. Thus, M.F.S. Lindenbergh, K. Shannon, M. T. McManus, J. P. Roose. “High-complexity shRNA libraries and PI3 kinase inhibition in cancer: high-fidelity synthetic lethality predictions”. Cell Reports 2019
• M.F.S. Lindenbergh, D.G.J. Koerhuis, E.G.F. Borg, E.M. van ’t Veld, T.A.P. Driedonks, R. Wubbolts, W. Stoorvogel, M. Boes. “Bystander T-cells support clonal T-cell activation by controlling the release of dendritic cell-derived immune-stimulatory extracellular vesicles”. Front. Imm. 2019
• M.F.S. Lindenbergh, W. Stoorvogel. “Antigen presentation by extracellular vesicles from professional antigen-presenting cells”.  Annu. Rev. Immunol. 2018
• A.M. Gram, T. Oosenbrug, M.F.S. Lindenbergh, C. Büll, A. Comvalius, K.J.I. Dickson, J. Wiegant, H. Vrolijk, R.J. Lebbink, R. Wolterbeek, G.J. Adema, M. Griffioen, M.H.M. Heemskerk, D.C. Tscharke, L. M. Hutt-Fletcher, E.J.H.J. Wiertz, R.C. Hoeben, M.E. Ressing. “The Epstein-Barr virus glycoprotein gp150 forms an immune-evasive glycan shield at the surface of infected cells”. PLoS Path. 2016
• M. van Gent, A.M. Gram, I.G.J. Boer, R.J. Geerdink, M.F.S. Lindenbergh, R.J. Lebbink, E.J. Wiertz, M.E. Ressing. “Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion”.  J. Gen. Virol. 2015.

Sprachen

• Niederländisch
• Englisch